Shanghai Fosun Pharmaceutical Group Co Ltd (2196.HK)
Company Info
Highlights
HK$61.42B
HK$1.06
12.52
1.00
HK$30.91B
HK$14.62B
HK$1.58B
HK$11.18 - HK$19.50
HK$16.59
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of HK$10,000 in Shanghai Fosun Pharmaceutical Group Co Ltd, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Shanghai Fosun Pharmaceutical Group Co Ltd had a return of -0.85% year-to-date (YTD) and 24.41% in the last 12 months. Over the past 10 years, Shanghai Fosun Pharmaceutical Group Co Ltd had an annualized return of -6.25%, while the S&P 500 had an annualized return of 9.70%, indicating that Shanghai Fosun Pharmaceutical Group Co Ltd did not perform as well as the benchmark.
2196.HK
-0.85%
-11.52%
-3.05%
24.41%
-11.16%
-6.25%
^GSPC (Benchmark)
-10.18%
-6.92%
-9.92%
5.42%
12.98%
9.70%
Monthly Returns
The table below presents the monthly returns of 2196.HK, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -6.95% | 16.01% | -1.71% | -6.55% | -0.85% | ||||||||
| 2024 | -22.00% | 6.79% | -9.60% | -3.75% | -0.65% | 8.01% | 0.48% | -4.01% | 25.04% | -5.01% | -3.24% | -1.54% | -15.12% |
| 2023 | 0.80% | -8.93% | -2.83% | 0.22% | -4.70% | -1.88% | 0.29% | -9.95% | -0.32% | -1.96% | -4.21% | -1.62% | -30.47% |
| 2022 | -9.17% | 0.32% | 22.36% | -11.49% | -2.51% | -10.26% | -2.24% | -10.74% | -24.89% | 4.10% | 30.17% | -3.10% | -25.70% |
| 2021 | -5.53% | 4.57% | -9.43% | 48.87% | 31.00% | -3.02% | 14.44% | -29.82% | -19.74% | -8.36% | 9.95% | -14.87% | -6.43% |
| 2020 | -11.06% | 5.02% | 16.17% | 16.08% | -16.89% | 5.28% | 43.31% | -10.64% | -1.83% | -0.93% | 2.35% | 13.65% | 59.67% |
| 2019 | 3.70% | 16.77% | 1.80% | -4.94% | -14.47% | 2.60% | 0.64% | -0.64% | -9.66% | 5.46% | -0.90% | 6.82% | 3.71% |
| 2018 | -9.37% | 0.22% | 5.82% | -10.89% | 17.00% | -14.33% | -11.96% | -15.35% | -2.68% | -23.83% | 14.89% | -14.81% | -53.58% |
| 2017 | 9.05% | 3.09% | 7.12% | 2.62% | 1.70% | 1.34% | -4.11% | 2.80% | 10.20% | 20.22% | -3.21% | 33.02% | 114.17% |
| 2016 | -17.60% | -2.80% | 18.76% | -1.40% | -4.27% | -4.56% | 0.64% | 18.30% | 7.11% | -1.04% | 2.31% | -2.66% | 7.67% |
| 2015 | 0.54% | -8.02% | 0.19% | 14.31% | 13.03% | -13.92% | -20.00% | 0.02% | 7.06% | 4.12% | -0.59% | -10.36% | -18.09% |
| 2014 | 2.14% | 15.93% | -2.35% | -2.96% | 9.92% | 0.35% | -10.90% | -0.79% | -0.60% | 11.38% | -0.36% | 0.36% | 21.12% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of 2196.HK is 64, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Shanghai Fosun Pharmaceutical Group Co Ltd (2196.HK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Shanghai Fosun Pharmaceutical Group Co Ltd provided a 2.15% dividend yield over the last twelve months, with an annual payout of HK$0.30 per share.
| Period | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | HK$0.30 | HK$0.30 | HK$0.46 | HK$0.66 | HK$0.52 | HK$0.43 | HK$0.36 | HK$0.46 | HK$0.40 | HK$0.38 | HK$0.36 | HK$0.34 |
Dividend yield | 2.15% | 2.13% | 2.71% | 2.64% | 1.51% | 1.16% | 1.53% | 2.00% | 0.80% | 1.59% | 1.58% | 1.22% |
Monthly Dividends
The table displays the monthly dividend distributions for Shanghai Fosun Pharmaceutical Group Co Ltd. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | ||||||||
| 2024 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.30 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.30 |
| 2023 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.46 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.46 |
| 2022 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.66 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.66 |
| 2021 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.52 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.52 |
| 2020 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.43 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.43 |
| 2019 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.36 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.36 |
| 2018 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.46 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.46 |
| 2017 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.40 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.40 |
| 2016 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.38 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.38 |
| 2015 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.36 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.36 |
| 2014 | HK$0.34 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.34 |
Dividend Yield & Payout
Dividend Yield
Payout Ratio
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Shanghai Fosun Pharmaceutical Group Co Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Shanghai Fosun Pharmaceutical Group Co Ltd was 84.57%, occurring on Apr 16, 2024. The portfolio has not yet recovered.
The current Shanghai Fosun Pharmaceutical Group Co Ltd drawdown is 80.60%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -84.57% | Aug 5, 2021 | 663 | Apr 16, 2024 | — | — | — |
| -62.8% | Mar 21, 2018 | 489 | Mar 16, 2020 | 278 | May 3, 2021 | 767 |
| -50.19% | Jun 1, 2015 | 162 | Jan 21, 2016 | 338 | Jun 8, 2017 | 500 |
| -21.94% | Jan 15, 2018 | 20 | Feb 9, 2018 | 25 | Mar 20, 2018 | 45 |
| -19.74% | Mar 12, 2014 | 26 | Apr 16, 2014 | 247 | Apr 21, 2015 | 273 |
Volatility
Volatility Chart
The current Shanghai Fosun Pharmaceutical Group Co Ltd volatility is 20.49%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Valuation
The Valuation section provides an overview of how Shanghai Fosun Pharmaceutical Group Co Ltd is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
PEG Ratio
PS Ratio
PB Ratio
Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Shanghai Fosun Pharmaceutical Group Co Ltd.
Loading data...
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |